Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias

Abstract

Dasatinib induces hematologic and cytogenetic responses in patients with CML or Ph-positive ALL who cannot tolerate or are resistant to imatinib. (ClinicalTrials.gov number, NCT00064233 [ClinicalTrials.gov].).